Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Karin Bok, Sandra Sitar, Barney S. Graham, et al.
Immunity (2021) Vol. 54, Iss. 8, pp. 1636-1651
Open Access | Times Cited: 238

Showing 1-25 of 238 citing articles:

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 342
Harnessing the microbiome to prevent global biodiversity loss
Raquel S. Peixoto, Christian R. Voolstra, Michael Sweet, et al.
Nature Microbiology (2022) Vol. 7, Iss. 11, pp. 1726-1735
Open Access | Times Cited: 168
Menstrual Symptoms After COVID-19 Vaccine: A Cross-Sectional Investigation in the MENA Region
Nadia Muhaidat, Mohammad Ali Alshrouf, Muayad Azzam, et al.
International Journal of Women s Health (2022) Vol. Volume 14, pp. 395-404
Open Access | Times Cited: 159
COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review
Christopher Peterson, Benjamin Lee, Kenneth Nugent
Vaccines (2022) Vol. 10, Iss. 6, pp. 948-948
Open Access | Times Cited: 159
Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials
Zhirong Yang, Yiwen Jiang, Fu-Xiao Li, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 4, pp. e236-e246
Open Access | Times Cited: 94
A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 86
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
Zezhong Liu, Jie Zhou, Wei Xu, et al.
Cell Research (2022) Vol. 32, Iss. 3, pp. 269-287
Open Access | Times Cited: 75
mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies
Zhenfei Xie, Ying‐Cing Lin, Jon M. Steichen, et al.
Science (2024) Vol. 384, Iss. 6697
Closed Access | Times Cited: 18
The Immunopathogenesis of a Cytokine Storm: The Key Mechanisms Underlying Severe COVID-19
Luka Hiti, Tijana Markovič, Mitja Lainščak, et al.
Cytokine & Growth Factor Reviews (2025)
Open Access | Times Cited: 7
SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants
John Charles Rotondo, Fernanda Martini, Martina Maritati, et al.
Viruses (2021) Vol. 13, Iss. 9, pp. 1687-1687
Open Access | Times Cited: 75
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans
István Vályi‐Nagy, Zsolt Matula, Márton Gönczi, et al.
GeroScience (2021) Vol. 43, Iss. 5, pp. 2321-2331
Open Access | Times Cited: 75
Delivering Pandemic Vaccines in 100 Days — What Will It Take?
Mélanie Saville, Jakob P. Cramer, M A Downham, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 2
Open Access | Times Cited: 60
Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines
Tomabu Adjobimey, Julia Meyer, Leander Sollberg, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 53
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
Violette Mouro, Alain Fischer
Mucosal Immunology (2022) Vol. 15, Iss. 4, pp. 584-594
Open Access | Times Cited: 51
Is vaccine confidence an unexpected victim of the COVID-19 pandemic?
Alessandro Siani, Amy Tranter
Vaccine (2022) Vol. 40, Iss. 50, pp. 7262-7269
Open Access | Times Cited: 40
Pandemic Preparedness and Response: Lessons From COVID-19
Anthony S. Fauci, Gregory K. Folkers
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 4, pp. 422-425
Open Access | Times Cited: 38
In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
S. Cankat, M. U. Demael, Leo Swadling
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 103-118
Open Access | Times Cited: 34
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 10
Time to invest in cholera
Rebecca C Stout, Nicholas Feasey, Marion Péchayre, et al.
EClinicalMedicine (2025) Vol. 80, pp. 103044-103044
Closed Access | Times Cited: 1
Development of Methods to Produce SARS CoV‐2 Virus‐Like Particles at Scale
Melissa A. Edeling, Linda Earnest, Julio Carrera Montoya, et al.
Biotechnology and Bioengineering (2025)
Open Access | Times Cited: 1
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 50
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
Jessica Widdifield, Jeffrey C. Kwong, Simon Chen, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 6, pp. e430-e440
Open Access | Times Cited: 38
Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
Chloé Dimeglio, Marion Migueres, Naémie Bouzid, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1548-1548
Open Access | Times Cited: 36
Immune Response to SARS-CoV-2 Vaccines
Navya Bellamkonda, Upendra P. Lambe, Sonali Sawant, et al.
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1464-1464
Open Access | Times Cited: 33
MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern
Jian Wang, Xuguang Yin, Yu Wen, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 4, pp. 3563-3574
Closed Access | Times Cited: 29
Page 1 - Next Page

Scroll to top